Neurocrine Biosciences Q3 2024 Adj. EPS $1.81 Beats $1.51 Estimate, Sales $622.100M Beat $600.628M Estimate
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences reported Q3 2024 earnings of $1.81 per share, surpassing the $1.51 estimate, and sales of $622.1M, exceeding the $600.628M estimate. This marks a significant year-over-year growth in both earnings and sales.
October 30, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences reported strong Q3 2024 results, with EPS of $1.81 beating estimates by 19.87% and sales of $622.1M exceeding expectations by 3.57%. This reflects a significant year-over-year growth in both earnings and sales.
The company's earnings and sales both exceeded analyst expectations, indicating strong financial performance. The significant year-over-year growth in both metrics suggests positive momentum, likely leading to a short-term increase in stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100